AAPL320.79-5.11 (-1.57%) ▼|ABBV255.00+1.70 (+0.67%) ▲|ABT100.97+0.40 (+0.40%) ▲|ACN138.14-1.96 (-1.40%) ▼|ADBE216.12-2.24 (-1.03%) ▼|AMAT572.38+18.46 (+3.33%) ▲|AMD550.03-2.30 (-0.42%) ▼|AMGN364.68-1.37 (-0.37%) ▼|AMT166.64+0.58 (+0.35%) ▲|AMZN234.79-10.06 (-4.11%) ▼|AVGO395.23-1.58 (-0.40%) ▼|AXP339.29-9.45 (-2.71%) ▼|BA209.55+0.90 (+0.43%) ▲|BAC61.02-0.61 (-0.98%) ▼|BKNG172.96-4.90 (-2.76%) ▼|BLK1,046.56-10.08 (-0.95%) ▼|BMY61.07+0.31 (+0.50%) ▲|BNY159.14-1.25 (-0.78%) ▼|BRK-B487.81-1.58 (-0.32%) ▼|C131.48-0.77 (-0.58%) ▼|CAT907.56+18.25 (+2.05%) ▲|CL89.86-1.77 (-1.93%) ▼|CMCSA23.02-0.51 (-2.15%) ▼|COF196.60-4.77 (-2.37%) ▼|COP121.79+3.00 (+2.53%) ▲|COST917.57-9.74 (-1.05%) ▼|CRM157.94-5.06 (-3.10%) ▼|CSCO113.21+1.00 (+0.89%) ▲|CVS106.68-0.74 (-0.69%) ▼|CVX197.39+4.41 (+2.29%) ▲|DE610.83+3.50 (+0.58%) ▲|DHR185.85+6.71 (+3.75%) ▲|DIS93.03-2.84 (-2.96%) ▼|DUK128.64+0.69 (+0.54%) ▲|EMR145.17+5.54 (+3.96%) ▲|FDX318.17-2.85 (-0.89%) ▼|GD383.99+10.83 (+2.90%) ▲|GE348.79+7.60 (+2.23%) ▲|GEV1,021.24+36.21 (+3.68%) ▲|GILD128.97-1.37 (-1.05%) ▼|GM79.25-2.88 (-3.51%) ▼|GOOG317.89-24.02 (-7.03%) ▼|GOOGL318.81-23.29 (-6.81%) ▼|GS1,074.15-24.05 (-2.19%) ▼|HD325.82-5.63 (-1.70%) ▼|HON247.04+14.05 (+6.03%) ▲|IBM206.29+0.52 (+0.25%) ▲|INTC103.61+0.99 (+0.97%) ▲|INTU282.62-1.85 (-0.65%) ▼|ISRG329.41-11.28 (-3.31%) ▼|JNJ255.92+0.29 (+0.11%) ▲|JPM347.23-0.98 (-0.28%) ▼|KO81.23-0.97 (-1.18%) ▼|LIN507.39-1.29 (-0.25%) ▼|LLY1,172.68+9.67 (+0.83%) ▲|LMT572.24+57.88 (+11.25%) ▲|LOW201.67-2.68 (-1.31%) ▼|LRCX324.61+5.32 (+1.67%) ▲|MA526.67-5.32 (-1.00%) ▼|MCD262.17-1.40 (-0.53%) ▼|MDLZ60.18-0.68 (-1.12%) ▼|MDT82.15+0.26 (+0.32%) ▲|META605.54-21.63 (-3.45%) ▼|MMM169.96-0.80 (-0.47%) ▼|MO72.27+0.10 (+0.14%) ▲|MRK129.66+2.19 (+1.72%) ▲|MS215.31-3.19 (-1.46%) ▼|MSFT383.62-6.73 (-1.72%) ▼|MU994.19+34.71 (+3.62%) ▲|NEE89.75+0.34 (+0.37%) ▲|NFLX68.31-0.22 (-0.32%) ▼|NKE41.20-1.02 (-2.40%) ▼|NOW97.16+1.70 (+1.78%) ▲|NVDA208.23-3.83 (-1.81%) ▼|ORCL123.64-2.21 (-1.75%) ▼|PEP134.22-1.44 (-1.06%) ▼|PFE24.90+0.08 (+0.30%) ▲|PG146.26-2.88 (-1.93%) ▼|PLTR123.38-1.19 (-0.96%) ▼|PM192.93-1.37 (-0.71%) ▼|QCOM172.54-3.09 (-1.76%) ▼|RTX209.65+14.77 (+7.58%) ▲|SBUX102.55-1.44 (-1.38%) ▼|SCHW102.30+1.50 (+1.49%) ▲|SO95.91+0.11 (+0.11%) ▲|SPG227.16+0.94 (+0.42%) ▲|T22.77-0.27 (-1.17%) ▼|TMO572.49+46.03 (+8.74%) ▲|TMUS180.64-10.30 (-5.39%) ▼|TSLA325.75-48.26 (-12.90%) ▼|TXN283.14-11.05 (-3.76%) ▼|UBER69.67-0.67 (-0.95%) ▼|UNH420.81-10.50 (-2.43%) ▼|UNP309.77+17.21 (+5.88%) ▲|UPS115.45-0.40 (-0.34%) ▼|USB63.15-1.32 (-2.05%) ▼|V349.45-3.97 (-1.12%) ▼|VZ44.29+0.00 (+0.00%) ▲|WFC85.78-0.64 (-0.74%) ▼|WMT107.08-2.25 (-2.06%) ▼|XOM157.81+3.36 (+2.18%) ▲|AAPL320.79-5.11 (-1.57%) ▼|ABBV255.00+1.70 (+0.67%) ▲|ABT100.97+0.40 (+0.40%) ▲|ACN138.14-1.96 (-1.40%) ▼|ADBE216.12-2.24 (-1.03%) ▼|AMAT572.38+18.46 (+3.33%) ▲|AMD550.03-2.30 (-0.42%) ▼|AMGN364.68-1.37 (-0.37%) ▼|AMT166.64+0.58 (+0.35%) ▲|AMZN234.79-10.06 (-4.11%) ▼|AVGO395.23-1.58 (-0.40%) ▼|AXP339.29-9.45 (-2.71%) ▼|BA209.55+0.90 (+0.43%) ▲|BAC61.02-0.61 (-0.98%) ▼|BKNG172.96-4.90 (-2.76%) ▼|BLK1,046.56-10.08 (-0.95%) ▼|BMY61.07+0.31 (+0.50%) ▲|BNY159.14-1.25 (-0.78%) ▼|BRK-B487.81-1.58 (-0.32%) ▼|C131.48-0.77 (-0.58%) ▼|CAT907.56+18.25 (+2.05%) ▲|CL89.86-1.77 (-1.93%) ▼|CMCSA23.02-0.51 (-2.15%) ▼|COF196.60-4.77 (-2.37%) ▼|COP121.79+3.00 (+2.53%) ▲|COST917.57-9.74 (-1.05%) ▼|CRM157.94-5.06 (-3.10%) ▼|CSCO113.21+1.00 (+0.89%) ▲|CVS106.68-0.74 (-0.69%) ▼|CVX197.39+4.41 (+2.29%) ▲|DE610.83+3.50 (+0.58%) ▲|DHR185.85+6.71 (+3.75%) ▲|DIS93.03-2.84 (-2.96%) ▼|DUK128.64+0.69 (+0.54%) ▲|EMR145.17+5.54 (+3.96%) ▲|FDX318.17-2.85 (-0.89%) ▼|GD383.99+10.83 (+2.90%) ▲|GE348.79+7.60 (+2.23%) ▲|GEV1,021.24+36.21 (+3.68%) ▲|GILD128.97-1.37 (-1.05%) ▼|GM79.25-2.88 (-3.51%) ▼|GOOG317.89-24.02 (-7.03%) ▼|GOOGL318.81-23.29 (-6.81%) ▼|GS1,074.15-24.05 (-2.19%) ▼|HD325.82-5.63 (-1.70%) ▼|HON247.04+14.05 (+6.03%) ▲|IBM206.29+0.52 (+0.25%) ▲|INTC103.61+0.99 (+0.97%) ▲|INTU282.62-1.85 (-0.65%) ▼|ISRG329.41-11.28 (-3.31%) ▼|JNJ255.92+0.29 (+0.11%) ▲|JPM347.23-0.98 (-0.28%) ▼|KO81.23-0.97 (-1.18%) ▼|LIN507.39-1.29 (-0.25%) ▼|LLY1,172.68+9.67 (+0.83%) ▲|LMT572.24+57.88 (+11.25%) ▲|LOW201.67-2.68 (-1.31%) ▼|LRCX324.61+5.32 (+1.67%) ▲|MA526.67-5.32 (-1.00%) ▼|MCD262.17-1.40 (-0.53%) ▼|MDLZ60.18-0.68 (-1.12%) ▼|MDT82.15+0.26 (+0.32%) ▲|META605.54-21.63 (-3.45%) ▼|MMM169.96-0.80 (-0.47%) ▼|MO72.27+0.10 (+0.14%) ▲|MRK129.66+2.19 (+1.72%) ▲|MS215.31-3.19 (-1.46%) ▼|MSFT383.62-6.73 (-1.72%) ▼|MU994.19+34.71 (+3.62%) ▲|NEE89.75+0.34 (+0.37%) ▲|NFLX68.31-0.22 (-0.32%) ▼|NKE41.20-1.02 (-2.40%) ▼|NOW97.16+1.70 (+1.78%) ▲|NVDA208.23-3.83 (-1.81%) ▼|ORCL123.64-2.21 (-1.75%) ▼|PEP134.22-1.44 (-1.06%) ▼|PFE24.90+0.08 (+0.30%) ▲|PG146.26-2.88 (-1.93%) ▼|PLTR123.38-1.19 (-0.96%) ▼|PM192.93-1.37 (-0.71%) ▼|QCOM172.54-3.09 (-1.76%) ▼|RTX209.65+14.77 (+7.58%) ▲|SBUX102.55-1.44 (-1.38%) ▼|SCHW102.30+1.50 (+1.49%) ▲|SO95.91+0.11 (+0.11%) ▲|SPG227.16+0.94 (+0.42%) ▲|T22.77-0.27 (-1.17%) ▼|TMO572.49+46.03 (+8.74%) ▲|TMUS180.64-10.30 (-5.39%) ▼|TSLA325.75-48.26 (-12.90%) ▼|TXN283.14-11.05 (-3.76%) ▼|UBER69.67-0.67 (-0.95%) ▼|UNH420.81-10.50 (-2.43%) ▼|UNP309.77+17.21 (+5.88%) ▲|UPS115.45-0.40 (-0.34%) ▼|USB63.15-1.32 (-2.05%) ▼|V349.45-3.97 (-1.12%) ▼|VZ44.29+0.00 (+0.00%) ▲|WFC85.78-0.64 (-0.74%) ▼|WMT107.08-2.25 (-2.06%) ▼|XOM157.81+3.36 (+2.18%) ▲|
23.7 C
New York
Thursday, July 23, 2026

Tag: liver damage

newssourceFORcompanyinformationcontent1releasesmarket

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Muscle Building Supplements 2025: CrazyBulk Introduces Effective Bodybuilding Supplements For Muscle Growth, Bulking, Cutting And Strength in USA

Muscle Building Supplements: A Game-Changer in Strength Training Programs 
Muscle Building Supplements: A Game-Changer in Strength Training Programs

Muscle Gain & Strength Supplements: How CrazyBulk Muscle Building Supplements Boost Strength and Maximize Muscle Performance Fast

Explore how CrazyBulk legal muscle building supplements power muscle gain, improve muscle strength, and unlock next-level muscle performance in 2025. 
Explore how CrazyBulk legal muscle building supplements power muscle gain, improve muscle strength, and unlock next-level muscle performance in 2025.

Safest SARMs For Muscle Growth 2025: CrazyBulk Introduces Effective SARMs For Bulking, Cutting and Strength in USA.

Albany, New York, July 15, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving world of fitness and bodybuilding, achieving optimal muscle growth, fat loss, and recovery without compromising health is paramount. Selective Androgen Receptor Modulators (SARMs) have emerged as a promising alternative to traditional anabolic steroids, offering similar benefits with reduced side effects. However, the safety and legality of SARMs vary, making it crucial for enthusiasts to exercise caution when choosing wisely.

Legal Steroid Alternatives for Muscle Growth 2025: CrazyBulk Introduces Effective Legal Steroid Alternatives For Bulking, Cutting, Fat Loss, and Strength in USA

New York City, NY, July 11, 2025 (GLOBE NEWSWIRE) --  CrazyBulk, a leading provider of legal steroid alternatives, is excited to announce its expanded line of top-rated, natural supplements designed to help athletes and fitness enthusiasts build muscle, enhance strength, and lose fat. These cutting-edge products are formulated to provide safe, effective results, mimicking the effects of anabolic steroids without the associated side effects and legal risks.

Finding Suggests Treatment Approach for Autoimmune Diseases

NEW YORK, June 30, 2025 /PRNewswire/ -- An engineered protein turns off the kind of immune cells most likely to damage tissue as part...

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLiver damage

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers